Probiotix Health PLC - PDMR Shareholding
Announcement provided by
ProBiotix Health Plc · PBX09/06/2025 16:15
9 June 2025
ProBiotix Health plc
("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")
PDMR Shareholding
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that a PDMR of the Company has acquired 67,500 ordinary shares of 0.05p each in the Company ("Ordinary Shares") as set out in the table below.
For further information, please contact:
|
ProBiotix Health plc |
|
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
Mark Anwyl Duncan Vasey |
Tel: 020 7220 9793 |
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. |
||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Michael Litichevski |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Vice President, Sales |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor |
|
|
a) |
Name |
ProBiotix Health plc |
|
b) |
LEI |
98450048683CF0388C30 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
ordinary shares of 0.05p each
ISIN: GB00BLNBFR86 |
|
b) |
Nature of the transaction |
Acquisition of ordinary shares |
|
c) |
Price(s) and volume(s) |
67,500 ordinary shares @ 7.7p per share |
|
d) |
Aggregated information - Aggregated volume - Price |
n/a - single transaction |
|
e) |
Date of the transaction |
9 June 2025 |
|
f) |
Place of the transaction |
Aquis Growth Market |
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
